Tatva Chintan Pharma Chem Share Price
1778.10+33.90 (+1.94%)
+62.68% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SOLARINDSNSE
PIDILITINDNSE
SRFNSE
FLUOROCHEMNSE
GODREJINDNSE
DEEPAKNTRNSE
AETHERNSE
ATULNSE
AARTIINDNSE
TATVANSE
Tatva Chintan Pharma Chem Share Price
1778.10+33.90 (+1.94%)
+62.68% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 11% | 6% | 32% |
| - | -4% | -3% | 636% |
| - | -5% | 3% | 63% |
| 19% | 10% | 4% | 6% |
Peer Comparison
Symbol
SOLARINDS
PIDILITIND
SRF
FLUOROCHEM
NAVINFLUOR
GODREJIND
DEEPAKNTR
AETHER
ATUL
AARTIIND
TATVA
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 19,480 | ₹178446 Cr | 89.61 | 72.11 | 250.42 | ₹1678 Cr |
| 1,522 | ₹161540 Cr | 60.98 | 8.57 | 29.89 | ₹2449 Cr |
| 2,533.8 | ₹75295 Cr | 34.83 | 25.6 | 102.33 | ₹1835 Cr |
| 4,471 | ₹49109 Cr | 79.85 | 20.09 | 90.49 | ₹577 Cr |
| 8,446 | ₹43357 Cr | 54.9 | 47.43 | 184.25 | ₹664 Cr |
| 1,091 | ₹37273 Cr | 31.7 | 8.44 | 50.37 | ₹1241 Cr |
| 1,600.9 | ₹22311 Cr | 28.48 | 25.29 | 74.81 | ₹551 Cr |
| 1,648 | ₹21914 Cr | 93.18 | 4.73 | 23.27 | ₹219 Cr |
| 6,135.5 | ₹18016 Cr | 22.65 | 83.32 | 378.24 | ₹678 Cr |
| 490.8 | ₹17812 Cr | 33.54 | 4.28 | 27.98 | ₹419 Cr |
| 1,728.6 | ₹4159 Cr | 80.95 | 6.83 | 38.4 | ₹42 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — |
| ₹23 Cr | ₹23 Cr | ₹23 Cr | ₹22 Cr | ₹22 Cr | ₹20 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
| ₹758 Cr | ₹715 Cr | ₹714 Cr | ₹493 Cr | ₹451 Cr | ₹146 Cr | ₹110 Cr | ₹72 Cr | ₹54 Cr |
| ₹758 Cr | ₹715 Cr | ₹714 Cr | ₹493 Cr | ₹451 Cr | ₹146 Cr | ₹110 Cr | ₹72 Cr | ₹54 Cr |
| ₹782 Cr | ₹739 Cr | ₹737 Cr | ₹515 Cr | ₹473 Cr | ₹166 Cr | ₹118 Cr | ₹80 Cr | ₹62 Cr |
| ₹5 Cr | ₹0 | ₹64 L | ₹4 Cr | ₹13 Cr | ₹27 Cr | ₹39 Cr | ₹32 Cr | ₹20 Cr |
| -₹10 Cr | -₹13 Cr | -₹12 Cr | -₹16 Cr | -₹9 Cr | ₹2 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr |
| ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹80,000 | ₹1 Cr | ₹3 L | ₹4 L | ₹52 L |
| ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹65 L | ₹55 L | ₹40 L | ₹29 L | ₹0 |
| -₹77 L | -₹11 Cr | -₹10 Cr | -₹11 Cr | ₹5 Cr | ₹31 Cr | ₹44 Cr | ₹35 Cr | ₹22 Cr |
| — | — | — | — | — | — | — | — | — |
| ₹58 Cr | ₹33 Cr | ₹45 Cr | ₹32 Cr | ₹45 Cr | ₹47 Cr | ₹32 Cr | ₹22 Cr | ₹25 Cr |
| ₹40 Cr | ₹25 Cr | ₹24 Cr | ₹50 Cr | ₹33 Cr | ₹21 Cr | ₹15 Cr | ₹11 Cr | ₹2 Cr |
| ₹114 Cr | ₹36 Cr | ₹10 Cr | ₹156 Cr | ₹92 Cr | ₹49 Cr | ₹40 Cr | ₹40 Cr | ₹36 Cr |
| ₹87 L | ₹3 Cr | ₹56 L | ₹2 Cr | ₹1 Cr | ₹11 Cr | ₹6 L | ₹4 L | ₹0 |
| ₹213 Cr | ₹96 Cr | ₹80 Cr | ₹241 Cr | ₹171 Cr | ₹128 Cr | ₹88 Cr | ₹73 Cr | ₹63 Cr |
| ₹994 Cr | ₹824 Cr | ₹807 Cr | ₹744 Cr | ₹649 Cr | ₹325 Cr | ₹249 Cr | ₹188 Cr | ₹147 Cr |
| ₹12 Cr | ₹7 Cr | ₹6 Cr | ₹1 Cr | ₹3 Cr | ₹51 L | ₹68 L | ₹43 L | ₹0 |
| ₹120 Cr | ₹36 Cr | ₹14 Cr | ₹170 Cr | ₹120 Cr | ₹90 Cr | ₹91 Cr | ₹77 Cr | ₹56 Cr |
| — | — | — | — | — | — | — | — | — |
| ₹733 Cr | ₹617 Cr | ₹488 Cr | ₹232 Cr | ₹186 Cr | ₹139 Cr | ₹122 Cr | ₹73 Cr | ₹70 Cr |
| ₹123 Cr | ₹89 Cr | ₹61 Cr | ₹36 Cr | ₹27 Cr | ₹18 Cr | ₹11 Cr | ₹7 Cr | ₹13 Cr |
| ₹609 Cr | ₹529 Cr | ₹427 Cr | ₹196 Cr | ₹160 Cr | ₹120 Cr | ₹111 Cr | ₹67 Cr | ₹56 Cr |
| ₹23 Cr | ₹22 Cr | ₹73 Cr | ₹231 Cr | ₹51 Cr | ₹10 Cr | ₹5 Cr | ₹6 Cr | ₹10 Cr |
| ₹4 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹47 L |
| ₹4 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹47 L |
| ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹30 L | ₹17 L | ₹38 L | ₹17 L |
| ₹2 Cr | ₹1 Cr | ₹83 L | ₹55 L | ₹51 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹645 Cr | ₹558 Cr | ₹509 Cr | ₹430 Cr | ₹214 Cr | ₹131 Cr | ₹116 Cr | ₹73 Cr | ₹67 Cr |
| — | — | — | — | — | — | — | — | — |
| ₹0 | ₹0 | ₹10 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹50 L |
| ₹196 Cr | ₹134 Cr | ₹153 Cr | ₹162 Cr | ₹170 Cr | ₹72 Cr | ₹64 Cr | ₹36 Cr | ₹29 Cr |
| ₹119 Cr | ₹90 Cr | ₹70 Cr | ₹84 Cr | ₹57 Cr | ₹91 Cr | ₹50 Cr | ₹41 Cr | ₹32 Cr |
| ₹9 Cr | ₹14 Cr | ₹38 Cr | ₹45 Cr | ₹177 Cr | ₹5 Cr | ₹11 Cr | ₹16 Cr | ₹9 Cr |
| ₹8 Cr | ₹6 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹3 Cr | ₹4 Cr | ₹1 Cr |
| ₹18 Cr | ₹21 Cr | ₹20 Cr | ₹17 Cr | ₹27 Cr | ₹20 Cr | ₹6 Cr | ₹18 Cr | ₹9 Cr |
| ₹350 Cr | ₹265 Cr | ₹298 Cr | ₹314 Cr | ₹436 Cr | ₹195 Cr | ₹133 Cr | ₹114 Cr | ₹80 Cr |
| ₹136 Cr | ₹169 Cr | ₹218 Cr | ₹74 Cr | ₹264 Cr | ₹66 Cr | ₹45 Cr | ₹42 Cr | ₹18 Cr |
| ₹994 Cr | ₹824 Cr | ₹807 Cr | ₹744 Cr | ₹649 Cr | ₹325 Cr | ₹249 Cr | ₹188 Cr | ₹147 Cr |
| ₹334 | ₹316 | ₹315 | ₹232 | ₹213 | ₹83 | ₹146 | ₹99 | ₹77 |
| ₹334 | ₹316 | ₹315 | ₹232 | ₹213 | ₹83 | ₹59 | ₹40 | ₹31 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|
| ₹57 Cr | ₹8 Cr | ₹44 Cr | ₹45 Cr | ₹104 Cr | ₹61 Cr | ₹48 Cr | ₹27 Cr | ₹0 |
| ₹44 Cr | ₹29 Cr | ₹29 Cr | ₹17 Cr | ₹12 Cr | ₹7 Cr | ₹9 Cr | ₹8 Cr | ₹0 |
| -₹62 Cr | -₹8 Cr | ₹34 Cr | -₹24 Cr | -₹77 Cr | -₹38 Cr | -₹23 Cr | -₹22 Cr | ₹0 |
| ₹39 Cr | ₹29 Cr | ₹107 Cr | ₹37 Cr | ₹39 Cr | ₹30 Cr | ₹34 Cr | ₹13 Cr | ₹0 |
| ₹31 Cr | ₹25 Cr | ₹98 Cr | ₹28 Cr | ₹20 Cr | ₹20 Cr | ₹25 Cr | ₹7 Cr | ₹0 |
| -₹116 Cr | -₹65 Cr | -₹121 Cr | -₹101 Cr | -₹197 Cr | -₹21 Cr | -₹40 Cr | -₹17 Cr | ₹0 |
| ₹79 Cr | ₹17 Cr | ₹31 Cr | ₹38 Cr | ₹235 Cr | -₹5 Cr | ₹10 Cr | ₹17 Cr | ₹0 |
| -₹5 Cr | -₹24 Cr | ₹8 Cr | -₹36 Cr | ₹59 Cr | -₹6 Cr | -₹5 Cr | ₹8 Cr | ₹0 |
| ₹11 Cr | ₹35 Cr | ₹27 Cr | ₹63 Cr | ₹4 Cr | ₹10 Cr | ₹16 Cr | ₹8 Cr | ₹0 |
| -₹19 L | ₹9 L | -₹8 L | -₹9 L | -₹2 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹6 Cr | ₹11 Cr | ₹35 Cr | ₹27 Cr | ₹63 Cr | ₹4 Cr | ₹11 Cr | ₹16 Cr | ₹0 |
Fundamental Ratios
Consolidated
Standalone
Tatva Chintan Pharma Chem Share Price
1778.10+33.90 (+1.94%)
+62.68% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 5
Bearish signals: 4 out of 9 oscillators
RSI
61.77Buy
STOCH %K
85.46Sell
MACD Level(12,26)
31.02Buy
Ultimate Oscillator
57.39Buy
Aroon Oscillator
28.00Sell
BOP
0.32Buy
CCI
140.24Sell
Williams %R
-14.54Sell
Momentum
161.20Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
1716.15Buy
SMA 9
1691.70Buy
EMA 21
1682.05Buy
SMA 21
1658.55Buy
EMA 50
1615.79Buy
SMA 50
1671.41Buy
EMA 200
1372.64Buy
SMA 200
1352.01Buy
WMA 20
1686.69Buy
Pivot
Pivot
Classic
Resistance 5
2106.23
Resistance 4
2020.73
Resistance 3
1935.23
Resistance 2
1849.73
Resistance 1
1796.97
Pivot
1764.23
Support 1
1711.47
Support 2
1678.73
Support 3
1593.23
Support 4
1507.73
Support 5
1422.23
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Tatva Chintan Pharma Chem Share Price
1778.10+33.90 (+1.94%)
+62.68% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% |
| 3.93% | 3.81% | 4.17% | 3.40% | 3.26% | 3.30% |
| 0.32% | 0.12% | 0.07% | 0.05% | 0.04% | 0.12% |
| 2.79% | 2.87% | 3.25% | 3.82% | 5.07% | 5.34% |
| 20.94% | 21.18% | 20.49% | 20.71% | 19.61% | 19.22% |
Bulk & block deals
Name
Musigma Securities
Graviton Research Capital Llp
Musigma Securities
Graviton Research Capital Llp
Graviton Research Capital Llp
Musigma Securities
Graviton Research Capital Llp
Musigma Securities
Graviton Research Capital Llp
Graviton Research Capital Llp
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 15 Oct 2025 | Purchase | 18.14 Cr | ₹1,262.14 | 1.44 L | Bulk | 0.614383 | NSE |
| 15 Oct 2025 | Purchase | 16.19 Cr | ₹1,210.89 | 1.34 L | Bulk | 0.571599 | NSE |
| 15 Oct 2025 | Sell | 18.14 Cr | ₹1,262.51 | 1.44 L | Bulk | 0.614383 | NSE |
| 15 Oct 2025 | Sell | 16.22 Cr | ₹1,212.74 | 1.34 L | Bulk | 0.571599 | NSE |
| 25 Jul 2025 | Purchase | 25.01 Cr | ₹1,152.08 | 2.17 L | Bulk | 0.927946 | NSE |
| 25 Jul 2025 | Purchase | 13.80 Cr | ₹1,170.74 | 1.18 L | Bulk | 0.50373 | NSE |
| 25 Jul 2025 | Sell | 25.05 Cr | ₹1,153.92 | 2.17 L | Bulk | 0.927946 | NSE |
| 25 Jul 2025 | Sell | 13.80 Cr | ₹1,171.36 | 1.18 L | Bulk | 0.50373 | NSE |
| 18 Jul 2025 | Purchase | 13.20 Cr | ₹1,035.16 | 1.28 L | Bulk | 0.545321 | NSE |
| 18 Jul 2025 | Sell | 13.21 Cr | ₹1,035.79 | 1.28 L | Bulk | 0.545321 | NSE |
Insider trading & SAST
Client name
Ajay Mansukhlal Patel Huf
Ajay Patel
Ajay Mansukhlal Patel & Pacs
Ajay Patel
Ajay Mansukhlal Patel (Huf)
Ajay Mansukhlal Patel
Nippon India Mutual Fund
Ajay Mansukhlal Patel Huf
Darshana Nitinkumar Shah
Shekhar Rasiklal Somani
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 Feb 2026 | Promoter | Disposal | 3.06 | — | 0 | — | 7.15 L | 06 Feb 2026 | Dissolution Of Huf | — | SAST | 29(2) | — |
| 18 Feb 2026 | Other | Acquisition | 3.06 | — | 0 | — | 7.15 L | 06 Feb 2026 | - | — | SAST | 10(6) | — |
| 18 Feb 2026 | Promoter | Acquisition | 3.06 | 20.16 | 0 | — | 7.15 L | 06 Feb 2026 | Dissolution Of Huf | 47,15,345 | SAST | 29(2) | — |
| 13 Feb 2026 | Promoter | Acquisition | 3.06 | — | 0 | — | 7.15 L | 06 Feb 2026 | — | — | SAST | 10(5) | — |
| 09 Feb 2026 | Promoter Group | Disposal | 3.058062 | 0 | 0 | — | 7.15 L | 06 Feb 2026 | Inter-se Transfer | 0 | Insider Trading | — | Equity Shares |
| 09 Feb 2026 | Promoter & Director | Acquisition | 3.058062 | 20.16 | 0 | — | 7.15 L | 06 Feb 2026 | Inter-se Transfer | 47,15,345 | Insider Trading | — | Equity Shares |
| 22 Jul 2025 | Other | Disposal | 0.12 | 3.16 | 0 | — | 28.61 K | 04 Jul 2023 - 03 Jul 2025 | Market | 7,40,251 | SAST | 29(2) | — |
| 13 Sep 2023 | Promoter | Disposal | 0.88 | 3.05 | 0 | — | 2.06 L | 06 Sep 2023 | Market | 7,15,345 | SAST | 29(2) | — |
| 13 Sep 2023 | Promoter | Disposal | 0.99 | 0.16 | 0 | — | 2.34 L | 06 Sep 2023 | Market | 39,628 | SAST | 29(2) | — |
| 13 Sep 2023 | Promoter | Disposal | 0.99 | 23.07 | 0 | — | 2.34 L | 06 Sep 2023 | Market | 53,96,861 | SAST | 29(2) | — |
Tatva Chintan Pharma Chem Share Price
1778.10+33.90 (+1.94%)
+62.68% past 1 Year
Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts
Corporate Actions
Date
Type
Details
Company details
Tatva Chintan Pharma Chem Share Price
1778.10+33.90 (+1.94%)
+62.68% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Tatva Chintan Pharma Chem Share Price
1778.10+33.90 (+1.94%)
+62.68% past 1 Year
News
Tatva Chintan Pharma Chem schedules investor and analyst meetings for September 23
Equity
TATVA
Tatva Chintan Pharma Chem to hold analyst and investor meet on 15 September
Equity
TATVA
Tatva Chintan approves Rs 200 crore greenfield capex for specialty chemicals
Equity
TATVA
Tatva Chintan Pharma Chem posts strong Q1 EBITDA growth and margin expansion
Equity
TATVA
Tatva Chintan Pharma Chem Q1 profit and revenue surge strongly year-on-year
Equity
TATVA
Tatva Chintan Pharma - Quaterly Results
Equity
TATVA
Tatva Chintan Pharma Chem reports sharp YoY expansion in Q4 EBITDA and margin
Equity
TATVA
Tatva Chintan Pharma Chem Q4 profit surges on strong revenue growth
Equity
TATVA
Tatva Chintan Pharma reports Profit after tax of 9.02 Crores, in the March 2026 quarter
Equity
TATVA
Tatva Chintan Pharma Chem informs about analyst meet
Equity
TATVA
Tatva Chintan Pharma Chem Faces 80% Natural Gas Supply Cap Under Government Order 2026.
Equity
TATVA
Tatva Chintan Pharma Chem informs about disclosure
Equity
TATVA
Tatva Chintan Pharma Chem informs about newspaper publication
Equity
TATVA
Tatva Chintan Pharma Chem Guides Agro and Pharma Intermediates Revenue Growth for 2027
Equity
TATVA
Tatva Chintan Pharma Chem Guides Electrolyte Salts to 7-8% Revenue Share by CY2026 from 1%.
Equity
TATVA
Tatva Chintan Pharma Chem Announces Jolva Greenfield Capex and Execution Timeline
Equity
TATVA
Tatva Chintan Pharma Chem Guides EBITDA Margins to 20-22% Range in FY27
Equity
TATVA
Tatva Chintan Pharma Chem Provides FY26-FY27 Revenue Growth Guidance of 20-30% YoY.
Equity
TATVA
Tatva Chintan Pharma Chem Management Guides for INR 850-900 Crores Revenue from Current Capacity in 2.5-3 Years.
Equity
TATVA
Tatva Chintan Pharma - Quaterly Results
Equity
TATVA

